Alpha Teknova, Inc. (TKNO): R&D Expense
$2.20M
Year ended 2025-12-31
$2.23M
Trailing 12 months to 2026-06-30
-34.3%
3-year compound annual growth
+7.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.20M | -20.4% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $2.76M | -50.4% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $5.57M | -28.0% | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | $7.74M | +79.4% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $4.31M | +186.1% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $1.51M | n/a | 2022-03-18, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $201.3K | -55.7% |
| Biomerica Inc (BMRA) | 2026-05-31 | $788.0K | -23.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $15.90M | +61.6% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $106.80M | -5.8% |
| Neogen Corp (NEOG) | 2026-05-31 | $18.40M | -12.8% |
Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗